Molecular Imaging of Hepatocellular Carcinoma Xenografts with Epidermal Growth Factor Receptor Targeted Affibody Probes

<table>Immunofluorescence and immunohistochemistry staining on subcutaneous HCC xenografts. (a) Immunofluorescence staining of Hep3B, PLC/PRF/5, and HepG2 xenografts using Alex680-<svg height="15.8625" id="M35" style="vertical-align:-3.41933pt" version="1.1" viewbox="0 0 66.762497 15.8625" width="66.762497" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink">
<g transform="matrix(.017,-0,0,-.017,.062,11.538)"><path d="M561 176l29 -6q-25 -130 -36 -170h-517l-8 15l420 599h-173q-77 0 -102 -7t-39 -29q-19 -29 -35 -87l-29 1q9 111 12 183h24q9 -16 19 -20.5t34 -4.5h399l7 -14l-413 -594q48 -6 163 -6q94 0 131.5 7.5t58.5 29.5q28 29 55 103z" id="x5A"></path></g>
<g transform="matrix(.012,-0,0,-.012,10.312,15.613)"><path d="M517 162l29 -4q-18 -100 -35 -158h-482v28q68 5 83.5 20t15.5 77v398q0 66 -13 80t-73 19v28h446q0 -8 8 -144l-29 -4q-11 51 -32 85q-11 17 -35 23t-78 6h-76q-23 0 -28 -5t-5 -27v-228h94q67 0 83 12t25 63h29v-191h-29q-10 54 -26 65.5t-81 11.5h-95v-189
q0 -65 24 -81q19 -13 104 -13q57 0 83 7t43 27q28 33 50 94z" id="x45"></path></g><g transform="matrix(.012,-0,0,-.012,17.071,15.613)"><path d="M692 302v-28q-45 -6 -54.5 -17t-9.5 -55v-86q0 -62 7 -95q-7 -2 -32 -7.5l-37 -8l-35.5 -7.5t-40.5 -7t-38.5 -4t-40.5 -2q-165 0 -266 93t-101 243q0 84 32 151t86 108t121.5 63t142.5 22q29 0 62.5 -4t52 -7.5t47.5 -10.5t31 -7l15 -156l-28 -6q-17 87 -66.5 121.5
t-128.5 34.5q-117 0 -191 -80.5t-74 -216.5q0 -56 17 -110t49.5 -100.5t87.5 -74.5t124 -28q53 0 87 17q17 9 24.5 23t7.5 43v85q0 54 -15.5 67.5t-89.5 18.5v28h254z" id="x47"></path></g><g transform="matrix(.012,-0,0,-.012,25.579,15.613)"><path d="M493 503l-29 -4q-13 56 -28 80q-13 22 -35.5 29.5t-78.5 7.5h-76q-22 0 -27.5 -5t-5.5 -27v-238h103q66 0 82.5 12t25.5 62h29v-193h-29q-9 54 -25.5 67t-82.5 13h-103v-181q0 -64 15 -78.5t84 -19.5v-28h-272v28q61 5 74.5 19.5t13.5 78.5v399q0 64 -13 78t-72 19v28
h440q1 -40 10 -147z" id="x46"></path></g><g transform="matrix(.012,-0,0,-.012,31.873,15.613)"><path d="M631 18l-4 -26q-24 0 -35 1q-57 3 -92.5 23t-69.5 68q-21 30 -101 160q-13 22 -30.5 31t-54.5 9h-32v-159q0 -63 14 -77.5t74 -19.5v-28h-262v28q62 5 76 19.5t14 77.5v402q0 62 -13 76t-73 19v28h248q109 0 159 -34q67 -42 67 -131q0 -115 -127 -172q27 -52 89 -144
q49 -71 81 -104q31 -36 72 -47zM212 316h48q73 0 108 29q55 42 55 124q0 76 -42 112t-104 36q-41 0 -54 -10q-11 -7 -11 -44v-247z" id="x52"></path></g>
<g transform="matrix(.012,-0,0,-.012,39.262,15.613)"><path d="M223 355q0 -25 -15.5 -41.5t-39.5 -16.5t-40 16.5t-16 41.5t16 41t40 16t39.5 -16t15.5 -41zM223 46q0 -26 -16 -42t-40 -16t-39.5 16t-15.5 42q0 24 16 40.5t39 16.5q24 0 40 -16.5t16 -40.5z" id="x2236"></path></g><g transform="matrix(.012,-0,0,-.012,43.237,15.613)"><path d="M384 0h-275v27q67 5 81.5 18.5t14.5 68.5v385q0 38 -7.5 47.5t-40.5 10.5l-48 2v24q85 15 178 52v-521q0 -55 14.5 -68.5t82.5 -18.5v-27z" id="x31"></path></g><g transform="matrix(.012,-0,0,-.012,48.948,15.613)"><path d="M244 635q90 0 143 -72t53 -177q0 -133 -65 -229.5t-171 -139.5q-79 -32 -140 -32l-5 30q109 18 185 91t101 186l-68 -36q-29 -16 -60 -16q-79 0 -129 51.5t-50 130.5q0 80 57 146.5t149 66.5zM228 602q-52 0 -78 -45.5t-26 -98.5q0 -69 36.5 -115.5t97.5 -46.5
q53 0 90 28q4 31 4 66q0 51 -9.5 95.5t-39 80.5t-75.5 36z" id="x39"></path></g><g transform="matrix(.012,-0,0,-.012,54.659,15.613)"><path d="M241 635q53 0 94 -28.5t63.5 -76t33.5 -102.5t11 -116q0 -58 -11 -112.5t-34 -103.5t-63.5 -78.5t-94.5 -29.5t-95 28t-64.5 75t-34.5 102.5t-11 118.5q0 58 11.5 112.5t34.5 103t64.5 78t95.5 29.5zM238 602q-32 0 -55.5 -25t-35.5 -68t-17.5 -91t-5.5 -105
q0 -76 10 -138.5t37 -107.5t69 -45q32 0 55.5 25t35.5 68.5t17.5 91.5t5.5 105t-5.5 105.5t-18 92t-36 68t-56.5 24.5z" id="x30"></path></g><g transform="matrix(.012,-0,0,-.012,60.371,15.613)"><path d="M447 623l8 -12l-283 -613l-74 -10l-7 11q174 283 297 551h-216q-48 0 -62.5 -12t-33.5 -63h-29q10 60 18 148h382z" id="x37"></path></g>
</svg>. (b) Immunohistochemistry (IHC) staining on paraffin-embedded subcutaneous tumor tissues, including Hep3B, PLC/PRF/5, and HepG2 tumors. Anti-EGFR antibody was used in 1 : 200 dilution. Nuclei staining was performed using Dako Cytomation Mayer’s hematoxylin histological staining reagent. (c) Representative photograph of PLC/PRF/5, Hep3B, and HepG2 subcutaneous tumors.</table>

BioMed Research International

fig3

Figure 3

Figure 3: Molecular Imaging of Hepatocellular Carcinoma Xenografts with Epidermal Growth Factor Receptor Targeted Affibody Probes 